Zacks: Brokerages Anticipate Repare Therapeutics Inc. (NASDAQ:RPTX) Will Announce Earnings of -$0.86 Per Share

Analysts predict that Repare Therapeutics Inc. (NASDAQ:RPTXGet Rating) will report earnings of ($0.89) per share for the current quarter, according to Zacks. Three analysts have made estimates for Repare Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.05) and the highest estimate coming in at ($0.80). Repare Therapeutics reported earnings per share of ($0.71) in the same quarter last year, which would suggest a negative year over year growth rate of 25.4%. The company is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Repare Therapeutics will report full year earnings of ($3.50) per share for the current year, with EPS estimates ranging from ($4.25) to ($2.92). For the next fiscal year, analysts expect that the business will report earnings of ($3.85) per share, with EPS estimates ranging from ($4.21) to ($3.17). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Repare Therapeutics.

Repare Therapeutics (NASDAQ:RPTXGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.03. Repare Therapeutics had a negative net margin of 1,533.38% and a negative return on equity of 47.99%.

RPTX has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $54.00 price target on shares of Repare Therapeutics in a research report on Tuesday, April 12th. Zacks Investment Research raised shares of Repare Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Piper Sandler dropped their price target on shares of Repare Therapeutics from $40.00 to $25.00 in a research report on Tuesday, April 12th. Stifel Nicolaus lowered shares of Repare Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, April 12th. Finally, The Goldman Sachs Group began coverage on shares of Repare Therapeutics in a research note on Thursday, March 17th. They issued a “buy” rating and a $43.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $44.50.

Shares of RPTX opened at $8.95 on Friday. Repare Therapeutics has a one year low of $8.75 and a one year high of $35.75. The company has a 50-day moving average of $12.50 and a two-hundred day moving average of $17.32. The stock has a market cap of $374.95 million, a price-to-earnings ratio of -2.92 and a beta of 0.89.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. boosted its stake in Repare Therapeutics by 1.9% during the first quarter. BlackRock Inc. now owns 467,311 shares of the company’s stock worth $6,655,000 after buying an additional 8,680 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Repare Therapeutics by 5.3% during the first quarter. JPMorgan Chase & Co. now owns 25,039 shares of the company’s stock worth $356,000 after buying an additional 1,253 shares in the last quarter. Sectoral Asset Management Inc. boosted its stake in Repare Therapeutics by 15.0% during the first quarter. Sectoral Asset Management Inc. now owns 237,785 shares of the company’s stock worth $3,386,000 after buying an additional 31,000 shares in the last quarter. Swiss National Bank boosted its stake in Repare Therapeutics by 7.0% during the first quarter. Swiss National Bank now owns 39,500 shares of the company’s stock worth $562,000 after buying an additional 2,600 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Repare Therapeutics by 9.5% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,580 shares of the company’s stock worth $165,000 after buying an additional 1,002 shares in the last quarter. Hedge funds and other institutional investors own 89.66% of the company’s stock.

Repare Therapeutics Company Profile (Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Featured Articles

Get a free copy of the Zacks research report on Repare Therapeutics (RPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repare Therapeutics (NASDAQ:RPTX)

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.